Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02888301 · ClinicalTrials.gov registry record

18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions

A clinical trial, sponsored by Jonsson Comprehensive Cancer Center.

Terminated
Registry status
12
Enrollment target

NCT02888301: Clinical Trial study, sponsored by Jonsson Comprehensive Cancer Center.

NCT02888301 is a clinical trial that was terminated before completion, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02888301 was terminated before completion, sponsored by Jonsson Comprehensive Cancer Center.

TERMINATED
Registry status
12 participants
Enrollment target

Study Summary

This clinical trial studies 18F-clofarabine positron emission tomography (PET)/computed tomography (CT) in imaging patients with cancer before and after treatment with a therapy that activates the patient's immune system (immunotherapy). PET/CT scans give detailed pictures of areas inside the body. 18F-clofarabine is a drug that contains a radioactive substance that is taken up by cells expressing deoxycytidine kinase (dCK), which is highly expressed in activated immune cells, making them light up during PET/CT scans. Doctors also want to know how 18F-clofarabine is distributed throughout the body before and after treatment with immunotherapies.

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Positron Emission Tomography
  • RADIATION Fluorine F 18 Clofarabine

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2015-06-12
Est. Completion 2018-04-30
Jonsson Comprehensive Cancer Center

321 total trials

Why NCT02888301 stopped before completion

NCT02888301 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.

The record links to 0 conditions, and to 3 interventions - of which Computed Tomography is the first listed.

NCT02888301 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02888301 about?

NCT02888301 is a clinical study titled "18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions". This clinical trial studies 18F-clofarabine positron emission tomography (PET)/computed tomography (CT) in imaging patients with cancer before and after treatment with a therapy that activates the patient's immune system (immunotherapy). PET/CT scans give detailed pictures of areas inside the body. ...

What is the current status of trial NCT02888301?

This trial is currently terminated. The enrollment target is 12 participants. The study started on 2015-06-12. Estimated completion is 2018-04-30.

What interventions are being tested in trial NCT02888301?

The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Fluorine F 18 Clofarabine (RADIATION).

Who is sponsoring clinical trial NCT02888301?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02888301, the US trial registry maintained by the National Library of Medicine. NCT02888301 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.